Stock listing

ASX:TRI TrivarX Limited Share Price

Home listing (ASX) of TrivarX Limited

Follow TrivarX Limited into a list and get an email when it puts out news.

Share price · ASX:TRI

$0.0080 AUD 0.0000 (0.0%)

Close on Nov 20, 2026

Past year -65.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0080 – $0.0080 AUDNov 20, 2026
Volume
37,500 sharesNov 20, 2026
Market cap
$9.23M AUDAt the close on Nov 20, 2026 · price × 1.15B shares outstanding
52-week range
$0.0070 – $0.0315 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$8,966 AUDMedian day 237,855 shares · 11 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
TrivarX Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:TRI · Home$0.0080 AUD0.0000 (0.0%)37,500$0.0080$0.0080$0.0080$0.0080Close on Nov 20, 2026
OTC:MDBIF$0.0029 USD0.0000 (0.0%)—$0.0029$0.0029$0.0029$0.0029Close on Nov 6, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:TRI · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00800.00000.0%$0.0080$0.0080$0.008037,500
$0.0080-0.0020-20.0%$0.0100$0.0100$0.00803,913,745
$0.01000.00000.0%$0.0100$0.0100$0.01001,111,787
$0.01000.00000.0%$0.0105$0.0105$0.0100365,899
$0.0100+0.0010+11.1%$0.0090$0.0115$0.00905,061,058
$0.0090-0.0010-10.0%$0.0100$0.0100$0.0090763,568
$0.01000.00000.0%$0.0100$0.0100$0.01000
$0.01000.00000.0%$0.0100$0.0100$0.010032,838
$0.01000.00000.0%$0.0100$0.0100$0.01000
$0.01000.00000.0%$0.0100$0.0100$0.01000
$0.0100-0.0010-9.1%$0.0100$0.0100$0.01001,375,736
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.0110+0.0010+10.0%$0.0105$0.0120$0.01051,439,556
$0.0100+0.0010+11.1%$0.0100$0.0100$0.01001,220,868
$0.0090+0.0010+12.5%$0.0080$0.0100$0.00805,191,136
$0.00800.00000.0%$0.0080$0.0080$0.00800
$0.00800.00000.0%$0.0080$0.0080$0.00800
$0.00800.00000.0%$0.0070$0.0080$0.0070188,416
$0.00800.00000.0%$0.0080$0.0080$0.0070129,642
$0.00800.00000.0%$0.0080$0.0080$0.0080350,050
$0.00800.00000.0%$0.0080$0.0080$0.0080272,761
$0.00800.00000.0%$0.0080$0.0080$0.0080425,000
$0.0080-0.0010-11.1%$0.0080$0.0080$0.00803,590,040
$0.00900.00000.0%$0.0090$0.0090$0.00900
$0.0090+0.0010+12.5%$0.0080$0.0090$0.0080200,195
$0.0080-0.0020-20.0%$0.0100$0.0100$0.0080821,150
$0.01000.00000.0%$0.0090$0.0100$0.00902,230,883
$0.01000.00000.0%$0.0100$0.0100$0.0100575,745
$0.01000.00000.0%$0.0100$0.0100$0.0095573,008
$0.01000.00000.0%$0.0110$0.0110$0.010041,166
$0.01000.00000.0%$0.0100$0.0100$0.01001,750
$0.01000.00000.0%$0.0100$0.0100$0.0100150,000
$0.01000.00000.0%$0.0100$0.0100$0.01004,500
$0.01000.00000.0%$0.0100$0.0100$0.0100362,681
$0.01000.00000.0%$0.0100$0.0100$0.01000
$0.01000.00000.0%$0.0100$0.0100$0.01000
$0.0100-0.0010-9.1%$0.0100$0.0100$0.0100477,426
$0.0110+0.0010+10.0%$0.0110$0.0110$0.0100300,000
$0.0100-0.0010-9.1%$0.0110$0.0110$0.0100298,675
$0.01100.00000.0%$0.0120$0.0120$0.0110104,515
$0.0110-0.0010-8.3%$0.0120$0.0120$0.0110165,520
$0.0120+0.0030+33.3%$0.0100$0.0120$0.01009,852,600
$0.0090-0.0030-25.0%$0.0110$0.0110$0.00902,776,332
$0.01200.00000.0%$0.0120$0.0120$0.0120196
$0.01200.00000.0%$0.0120$0.0120$0.01200
$0.01200.00000.0%$0.0115$0.0120$0.0115528,186
$0.01200.00000.0%$0.0120$0.0120$0.011092,058
$0.01200.00000.0%$0.0120$0.0120$0.01201,418,339
$0.0120-0.0005-4.0%$0.0120$0.0120$0.012045,000
$0.0125+0.0005+4.2%$0.0120$0.0125$0.0120497,840
$0.0120-0.0020-14.3%$0.0120$0.0120$0.0120115,833
$0.0140-0.0010-6.7%$0.0140$0.0140$0.01303,356,083
$0.0150+0.0010+7.1%$0.0150$0.0150$0.0150763,635
$0.0140-0.0010-6.7%$0.0140$0.0140$0.0140237,855
$0.01500.00000.0%$0.0150$0.0150$0.0150139,124
$0.01500.00000.0%$0.0150$0.0150$0.015050,000
$0.01500.00000.0%$0.0150$0.0150$0.0150862,461
$0.01500.00000.0%$0.0150$0.0155$0.0150535,939
$0.01500.00000.0%$0.0140$0.0150$0.01401,541,348
$0.0150-0.0010-6.3%$0.0150$0.0160$0.0140986,899
$0.01600.00000.0%$0.0150$0.0160$0.015029,500
$0.0160+0.0010+6.7%$0.0160$0.0160$0.0160256,405
$0.01500.00000.0%$0.0150$0.0150$0.01508,124
$0.01500.00000.0%$0.0150$0.0150$0.015062,209
$0.01500.00000.0%$0.0150$0.0150$0.01509,467
$0.01500.00000.0%$0.0150$0.0150$0.015097,181

Splits

2 splits since 2015 · ASX:TRI · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-100Consolidation
Ticker
ASX:TRI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All TrivarX Limited news

TrivarX Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 194 in all · newest Nov 10, 2026 · oldest 2010
Decks
5 decks · latest Jun 25, 2026

Where TrivarX Limited is listed

ListingExchangeCountryCurrency
ASX:TRI · Home listing · This pageASXAustraliaAUD
OTC:MDBIFOTCUnited StatesUSD

Valuation

Price/book 0.6× against a median of 2.1×: the lowest of 9 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$6.91M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
TrivarX Limited · ASX:TRIUS$6.11MUS$4.58Mn/an/an/a0.6×n/a0.0×n/a
FibroBiologics, Inc. · NASDAQ:FBLGUS$6.34MUS$5.17Mn/an/an/a3.5×n/a0.0×0.34
GT Biopharma, Inc. · NASDAQ:GTBPUS$6.33M−US$3.60Mn/an/an/a0.8×n/a0.0×1.57
Kyntra Bio, Inc. · NASDAQ:KYNBUS$6.32M−US$33.97Mn/a−6.4×n/an/a−326.0%n/a1.58
Acurx Pharmaceuticals, Inc. · NASDAQ:ACXPUS$6.30M−US$3.35Mn/an/an/a0.9×n/a0.0×1.31
Enveric Biosciences, Inc. · NASDAQ:ENVBUS$6.04MUS$429,455n/an/an/a1.1×n/a0.0×0.76
Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDBUS$6.03MUS$6.03Mn/a314×n/a5.4×n/a0.0×n/a
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Marvel Biosciences Corp · TSXV:MRVLUS$5.91MUS$6.04Mn/an/an/an/an/an/a0.91
Exicure, Inc. · NASDAQ:XCURUS$5.89MUS$4.67Mn/an/an/a3.1×n/a0.0×0.49
Median of the othersUS$6.04MUS$3.20M68.2×2.1×−326.0%0.0×0.91

Team and board

Officers

OfficerRole
Danielle MeyrickChief Executive Officer
Kai SunChief Operating Officer
Tony KeatingExecutive Director

Board

DirectorRole
David TrimboliNon-executive Chairman
Chris NtoumenopoulosNon-executive Director
Tony KeatingExecutive Director

Events

QuarterResultsShare move
Q4 2025Sep 29, 20250.0%
Q2 2025Feb 28, 20250.0%
Q2 2023Feb 24, 2023 · After close0.0%
Q4 2022Sep 30, 20220.0%
Q2 2022Feb 25, 2022−25.0%
Q4 2021Aug 31, 2021+7.1%
Q2 2021Feb 24, 2021−9.1%

Open Events

Decks

DeckKindSlidesDate
JP Equity Partners 'Boom of the Biotech II' Investor Briefing (June 2026)Conference17 slidesJun 25, 2026
TechKnow Invest Roadshow July 2024Conference19 slidesJul 30, 2024
Investor Presentation (May 2024)Investor deck16 slidesMay 22, 2024
Investor Presentation (November 2023)Investor deck18 slidesNov 16, 2023
Shareholder Meeting (November 2020)Shareholder meeting16 slidesNov 12, 2020

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue1.13M893.3K22.1K40.0K101.7K133.5K364.6K204.9K23.1K
Cost of revenue6.47M52.5K93.1K1581.07K170.7K204.7K226.1K75.7K0
Gross profit-6.47M-52.5K-93.1K21.9K39.0K-69.0K-71.2K138.5K129.2K23.1K
Research and development10.3K26.4K14.3K307.1K802.9K430.8K360.0K394.9K3.26M4.32M
Selling, general and administrative1.30M974.3K1.07M701.3K1.05M1.19M1.87M4.54M9.49M2.90M
Operating income-8.42M-2.04M-2.31M-2.68M-3.64M-2.63M-3.84M-6.57M-18.7M-12.7M
Depreciation and amortization6.47M52.5K93.1K97.5K448.9K198.5K148.9K148.9K1.33M1.73M
EBITDA-1.95M-1.99M-2.22M-2.58M-3.19M-2.44M-3.69M-6.42M-17.4M-10.9M
Interest expense12.5K33.6K13.4K13.3K5.32K6.29K36.7K13.9K8.14K0
Income before tax-8.76M-1.97M-1.24M-3.12M-12.7M-1.49M-3.87M-6.59M-16.3M-9.79M
Income tax-1.03M955.0K8.69K1.17M828.5K-148.9K00
Net income-8.76M-943.2K-1.24M-3.12M-12.7M-1.49M-4.70M-6.59M-16.3M-9.79M
Earnings per share, basic-0.96-0.00-0.00-0.02-0.12-0.02-0.01-0.03-0.08-0.08

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents2.44M1.25M848.1K214.1K1.03M2.31M812.5K1.33M6.12M5.01M
Short-term investments0
Receivables032.2K32.5K14.9K1.67M220.3K
Current assets2.49M1.30M915.2K304.5K1.20M2.66M861.7K1.53M7.89M7.37M
Property, plant and equipment164.3K15.4K107.5K65.4K23.1K71.4K
Goodwill0309.1K
Total assets16.5M13.5M10.8M7.89M8.49M17.4M14.0M13.3M19.1M19.3M
Accounts payable316.2K440.0K948.7K1.38M1.00M760.8K1.20M1.01M1.24M939.8K
Current liabilities473.4K696.8K1.18M1.76M1.38M963.7K1.40M4.70M5.08M5.94M
Long-term debt0
Total debt128.1K169.0K15.9K103.7K66.4K24.8K76.9K2.75M120.0K132.5K
Total liabilities565.6K831.2K1.18M1.76M1.38M963.7K1.40M4.70M5.08M5.94M
Shareholders' equity16.0M12.7M9.88M6.30M7.11M16.4M12.6M8.60M14.0M13.3M
Shares outstanding9.17M494.8M334.3M178.1M102.5M73.6M882.4M226.0M203.9M124.3M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-1.51M-189.7K-1.48M-932.1K-12.3M-1.70M-3.59M-6.85M-12.3M-5.42M
Capital spending-1.51M-2.09M-2.85M-2.26M-3.11M-1.83M-1.54M-1.14M00
Free cash flow-2.67M-189.7K-3.70M-3.19M-15.4M-3.53M-5.13M-7.99M-12.3M-5.42M
Cash from investing-1.17M-2.09M-2.85M-2.26M-3.11M-1.83M-1.50M-1.06M-399.6K34.2K
Cash from financing3.87M2.68M4.32M2.47M3.33M4.92M4.55M3.12M13.8M9.36M
Dividends paid0
Share buybacks2.73M4.70M2.51M3.38M4.97M-140.9K-1.05M-1.20M
Change in cash1.20M398.7K634.0K-818.5K-1.28M1.50M-520.6K-4.79M1.11M3.97M

Open Financials

Filings

FilingDateTypeFiled with
TrivarX Appoints Emeritus Research for Phase 1 StudyNov 10, 2026Operations updateASX
September 2026 Quarterly Activities Report and Appendix 4COct 29, 2026Quarterly reportASX
September 2026 Quarterly Activities Report and Appendix 4COct 29, 2026Quarterly reportASX
Letter to Shareholders & Notice of AGM & Proxy FormOct 26, 2026Meeting noticeASX
Syntro Health Appointed to Support Stabl-Im Clinical ProgramOct 21, 2026Operations updateASX
Syntro Health Appointed to Support Stabl-Im Clinical ProgramOct 21, 2026Operations updateASX
Change of Director's Interest Notice - David TrimboliOct 14, 2026Ownership change noticeASX
Change of Director's Interest Notice - Chris NtoumenopoulosOct 14, 2026Ownership change noticeASX
Notification of cessation of securities - TRIOct 14, 2026FinancingASX
Appendix 4GSep 29, 2026Other filingsASX
All 193 filings
FilingDateTypeFiled with
Corporate Governance StatementSep 29, 2026Other filingsASX
2026 Annual ReportSep 29, 2026Annual reportASX
Stabl-Im Clinical Development UpdateSep 22, 2026Operations updateASX
Notice of AGM and Closing Date for Director NominationsSep 21, 2026Meeting noticeASX
Appendix 4E - Preliminary Final ReportAug 26, 2026ResultsASX
June 2026 Quarterly Activities Report and Appendix 4CJul 28, 2026Quarterly reportASX
Stabl-Im clinical trial supply milestone achievedJul 15, 2026Operations updateASX
CRO Engaged to Advance Stabl-Im Phase 1 TrialMay 21, 2026Operations updateASX
March 2026 Quarterly Activities Report and Appendix 4CApr 29, 2026Quarterly reportASX
Dr Danielle Meyrick appointed as CEOApr 28, 2026Management or board changeASX
Appendix 4D & Half-Year Financial Report to 31 December 2025Feb 24, 2026Interim reportASX
December 2025 Quarterly Activities Report and Appendix 4CJan 29, 2026Quarterly reportASX
Positive results from US-veteran mental health trialDec 17, 2025ResultsASX
TRI Exercises Option to Advance Acquisition of Stabl-ImNov 4, 2025Acquisition or disposalASX
September 2025 Quarterly Activities Report and Appendix 4COct 30, 2025Quarterly reportASX
US-veteran mental health trial patient recruitment completeOct 21, 2025Operations updateASX
Acquisition of Stabl-Im technology and Private PlacementOct 15, 2025FinancingASX
Reinstatement to Official QuotationOct 15, 2025Trading halt or suspensionASX
Extension of Trading SuspensionOct 12, 2025Trading halt or suspensionASX
Suspension from QuotationOct 8, 2025Trading halt or suspensionASX
Inadvertent Lift of Trading HaltOct 8, 2025Trading halt or suspensionASX
Pause in tradeOct 7, 2025Trading halt or suspensionASX
Positive interim results from US-veteran focused trialOct 7, 2025ResultsASX
Trading HaltOct 6, 2025Trading halt or suspensionASX
Appendix 4E - Preliminary Final ReportAug 28, 2025ResultsASX
June 2025 Quarterly Activities Report and Appendix 4CJul 30, 2025Quarterly reportASX
First patient recruited in innovative mental health trialJun 18, 2025Operations updateASX
March 2025 Quarterly Activities Report and Appendix 4CApr 30, 2025Quarterly reportASX
IRB approval for trial with US Dept of Veterans AffairsApr 27, 2025Operations updateASX
TrivarX Receives Firm Commitments to Raise $2.25 millionMar 16, 2025FinancingASX
Trial with US Department of Veterans AffairsMar 12, 2025Operations updateASX
Appendix 4D & Half-Year Financial Report to 31 December 2024Feb 28, 2025Interim reportASX
December 2024 Quarterly Activities Report and Appendix 4CJan 30, 2025Quarterly reportASX
TrivarX Receives $1.03m R&D Tax IncentiveDec 5, 2024Other filingsASX
New AI Tool Expands Patient Reach and Market OpportunitiesNov 6, 2024Operations updateASX
September 2024 Quarterly Activities Report and Appendix 4COct 30, 2024Quarterly reportASX
June 2024 Quarterly Activities Report and Appendix 4CJul 31, 2024Quarterly reportASX
Positive Results from Phase 2 SAMDE StudyJul 29, 2024Other filingsASX
TrivarX Receives Firm Commitments to Raise $2.5 millionMay 1, 2024Other filingsASX
March 2024 Quarterly Activities Report and Appendix 4CApr 29, 2024Quarterly reportASX
Appendix 4D & Half-Year Financial Report to 31 December 2023Feb 28, 2024Interim reportASX
Response to ASX Price QueryFeb 22, 2024Explanation requestASX
TrivarX Receives $888k R&D Tax IncentiveFeb 7, 2024Other filingsASX
TRI-001 Algorithm and Phase 2 Trial UpdateFeb 4, 2024Other filingsASX
December 2023 Quarterly Activities Report and Appendix 4CJan 31, 2024Quarterly reportASX
Phase 2 SAMDE Study UpdateNov 19, 2023Other filingsASX
Board and Management TransitionOct 5, 2023Other filingsASX
Letter to Shareholders & Notice of GM & Proxy FormSep 6, 2023Other filingsASX
Phase 2 Trial Commences for SAMDE StudySep 3, 2023Other filingsASX
Proposed issue of securities - MEBAug 7, 2023FinancingASX
Medibio Receives Firm Commitments to Raise $2.25mAug 7, 2023Other filingsASX
June 2023 Quarterly Activities Report and Appendix 4CJul 30, 2023Quarterly reportASX
Phase 1 Trial Completed for SAMDE StudyJul 23, 2023Other filingsASX
Medibio Completes Share Purchase PlanMay 29, 2023FinancingASX
March 2023 Quarterly Activities Report and Appendix 4CApr 26, 2023Quarterly reportASX
MEB Executes Bridging Loans with DirectorsApr 21, 2023Other filingsASX
Share Purchase Plan Supplementary ProspectusApr 14, 2023FinancingASX
Share Purchase Plan ProspectusMar 1, 2023FinancingASX
Half Yearly Report and AccountsFeb 24, 2023Interim reportASX
MEB to Raise up to $2.75 million By Way of a Placement & SPPFeb 14, 2023FinancingASX
Medibio Quarterly Update and Cashflow ReportJan 30, 2023Other filingsASX
Medibio Receives R&D Tax Incentive RefundNov 14, 2022Other filingsASX
Medibio Appoints CEOSep 19, 2022Other filingsASX
Appendix 4E and Preliminary Final ReportAug 31, 2022ResultsASX
Sleep Analysis Depressive Burden Study Clinical TrialJul 20, 2022Other filingsASX
MEB to Raise $1.4m by way of a Placement & MD/CEO ResignsJun 22, 2022FinancingASX
Reinstatement to QuotationJun 22, 2022Trading halt or suspensionASX
Voluntary SuspensionJun 16, 2022Trading halt or suspensionASX
FDA Confirm Diagnostic Method on Depression Validation TrialMay 18, 2022Other filingsASX
Medibio Announces Entitlement Offer ResultMar 10, 2022FinancingASX
Termination of Underwriting AgreementMar 1, 2022Other filingsASX
Non-Renounceable Entitlement Offer Underwriting UpdateJan 20, 2022FinancingASX
MEB to Raise up to $5.7 million by way of a Placement & NREODec 14, 2021FinancingASX
FDA Strategy and Regulatory UpdateOct 25, 2021Other filingsASX
Appendix 4E and Annual ReportAug 31, 2021Annual reportASX
MEB Appoints R&CPMK As Communications Agency in the USJun 24, 2021Other filingsASX
Medibio strengthens its IP protectionMay 3, 2021Other filingsASX
Re-submission of FDA 510(k) applicationApr 28, 2021Other filingsASX
Consumer Mental Health App Development - Second Test PhaseApr 21, 2021Other filingsASX
MEB Share Purchase Plan Closes Strongly OversubscribedMar 31, 2021FinancingASX
Supplementary ProspectusMar 31, 2021Offer documentASX
MEB Begins Implementation of ilumen In the United KingdomMar 18, 2021Other filingsASX
Underwritten Share Purchase Plan UpdateFeb 15, 2021FinancingASX
MEB to Raise up to $3.5m By Way of a Placement and SPPFeb 10, 2021FinancingASX
Medibio Granted CE Mark Approval for MEBsleepJan 18, 2021Other filingsASX
Consumer Mental Health App Initial testing phase commencedJan 10, 2021Other filingsASX
US FDA advises further data needed for MEBsleep approvalDec 28, 2020Other filingsASX
Update on Breakthrough Device ProgramDec 3, 2020Other filingsASX
Global Master License & Services Agreement with CompassNov 22, 2020Other filingsASX
AGM PresentationNov 12, 2020Other filingsASX
MEB Signs Clinical Trial Agreement with MedBridge HealthcareOct 6, 2020Other filingsASX
Request For FDA Breakthrough Device Designation SubmittedOct 1, 2020Other filingsASX
Patent Granted to Monitor Stress Conditions Using HeartrateAug 9, 2020Other filingsASX
Entitlement Issue ResultsJul 9, 2020FinancingASX
Entitlement Offer BookletJun 10, 2020FinancingASX
Placement and Fully Underwritten Entitlement OfferJun 9, 2020FinancingASX
Medibio submits FDA 510K Application to FDAApr 29, 2020Other filingsASX
Final Compass Pilot Completed SuccessfullyApr 8, 2020Other filingsASX
Strategic Plan for FDA and CE Mark ApprovalFeb 13, 2020Other filingsASX
Company UpdateDec 8, 2019Other filingsASX
Results of Annual General MeetingNov 22, 2019Meeting outcomeASX
Pause in TradingNov 21, 2019Trading halt or suspensionASX
Medibio Signs Agreement with PwC Australia for ilumenOct 23, 2019Other filingsASX
MEB successfully completes first Ilumen pilot with CompassOct 20, 2019Other filingsASX
Medibio Announces Results of Review of Partly Paid SharesSep 26, 2019Other filingsASX
Fourth Pilot Agreement Signed with Compass Group for ilumenAug 30, 2019Other filingsASX
Board Changes and Establishment of Advisory BoardAug 29, 2019Other filingsASX
MEB Signs Compass Group Australia to ilumenJul 29, 2019Other filingsASX
MEB Partners with Corporate Wellness Solution Leader WellteQJul 28, 2019Other filingsASX
MEB Signs Second Compass Group PLC Pilot for ilumenJul 19, 2019Other filingsASX
MEB Raises $4.02m via Placement and Fully Underwritten SPPJul 9, 2019FinancingASX
Suspension from Official QuotationJul 8, 2019Trading halt or suspensionASX
MEB Signs Compass Group to ilumenJun 30, 2019Other filingsASX
Response to Appendix 4C QueryMay 20, 2019Quarterly reportASX
Regulatory and Commercialisation Strategy UpdateApr 29, 2019Other filingsASX
Sponsored Research Agreement with Humanitas UniversityApr 16, 2019Other filingsASX
MEB Outsources Psychology Services in support of ilumenMar 13, 2019Other filingsASX
Entitlement Issue Results and Shortfall NotificationMar 12, 2019FinancingASX
Ilumen Successfully Completes First Commercial ProgramMar 6, 2019Other filingsASX
Converting Note & Non-Renounceable Entitlement OfferDec 9, 2018FinancingASX
Exclusive Agreement Signed for ilumen Pilot ProgramNov 26, 2018Other filingsASX
Response to ASX Appendix 4C QueryNov 14, 2018Explanation requestASX
Medibio Provides Update on FDA ProcessNov 8, 2018Other filingsASX
Medibio Appoints CEO and Managing DirectorNov 1, 2018Other filingsASX
MEB Signs ilumen Contract with Large Australian EmployerOct 23, 2018Other filingsASX
Receipt of R&D Tax Incentive RefundOct 14, 2018Other filingsASX
Medibio Releases Corporate Health Product, ilumenOct 3, 2018Other filingsASX
Notice Received Under Section 249D of the Corporations ActOct 1, 2018Other filingsASX
Executive Leadership ChangesSep 20, 2018Other filingsASX
Clinical Study Shows Improvement to Diagnostic StandardSep 5, 2018Other filingsASX
Preliminary Final ReportAug 29, 2018ResultsASX
Departure of Managing Director & Chief Executive OfficerAug 28, 2018Other filingsASX
Medibio Submits FDA De Novo ApplicationJul 15, 2018Other filingsASX
Medibio Receives TGA ApprovalJun 19, 2018Other filingsASX
MEB Signs Global Contract with Jacobs EngineeringMay 25, 2018Other filingsASX
Medibio Announces Next Tranche of Corporate Health ContractsMay 9, 2018Other filingsASX
Medibio Signs First Corporate Health ContractMay 8, 2018Other filingsASX
Medibio Receives CE CertificationMay 2, 2018Other filingsASX
MEB signs binding term sheet to acquire Vital ConversationsMar 4, 2018Acquisition or disposalASX
Medibio Quarterly Update and Cash Flow ReportJan 30, 2018Other filingsASX
Agreement with Striiv to Accelerate CommercialisationJan 21, 2018Other filingsASX
Medibio Announces ISO 13485 CertificationJan 10, 2018Other filingsASX
Medibio & Mayo Clinic collaborate on depression technologyDec 13, 2017Other filingsASX
Appendix 4C - quarterlyOct 30, 2017Quarterly reportASX
MEB completes heavily oversubscribed institutional placementOct 12, 2017FinancingASX
Response to ASX QueryOct 10, 2017Explanation requestASX
Medibio enters into an Agreement with Otsuka PharmaceuticalOct 8, 2017Other filingsASX
Medibio enters agreement with Mayo ClincOct 3, 2017Other filingsASX
Medibio initiates confirmatory studyAug 21, 2017Other filingsASX
Medibio announces positive clinical study resultsAug 2, 2017Other filingsASX
Quarterly ASX Update and CashflowsJul 27, 2017Other filingsASX
Scientific breakthrough on objective diagnosis of PTSDJun 26, 2017Other filingsASX
Independent researchers present first data validating MEBJun 8, 2017Other filingsASX
Signed second agreement for WellnessMay 17, 2017Other filingsASX
MEB Signs Strategic Joint Development Agreement with Mayo ClMay 10, 2017Other filingsASX
Quarterly ASX Update and CashflowApr 27, 2017Other filingsASX
MEB enters fully funded Paediatric mental illness diagnosticApr 10, 2017Other filingsASX
Conversion of Options to Partly Paid sharesApr 5, 2017Other filingsASX
MEB appoints US med-tech veteran as CEO & Managing DirectorFeb 16, 2017Other filingsASX
Early Redemption of Convertible NoteJan 30, 2017FinancingASX
Partnership with leading US University on PTSDJan 24, 2017Other filingsASX
Excellent performance in the pilot phase of US ValidationDec 20, 2016Other filingsASX
Medibio enters into binding agreement with MedtronicNov 24, 2016Other filingsASX
Capital raising of $13.5million to accelerate growthNov 17, 2016FinancingASX
Outstanding 86% accuracy in 889 person Ottawa Uni studyNov 1, 2016Other filingsASX
Quarterly Activities ReportOct 31, 2016Quarterly reportASX
Receipt of $3,074,224 R & D Tax Incentive RefundOct 14, 2016Other filingsASX
Partners with HBF and Vital Conversations on mental healthOct 10, 2016Other filingsASX
Funding UpdateOct 9, 2016Other filingsASX
Medibio and Monash Groundbreaking partnership on innovationSep 14, 2016Other filingsASX
Commercial Trial and Validation UpdateAug 17, 2016Other filingsASX
Breakthrough validation of depression test with Ottawa UnivAug 8, 2016Other filingsASX
MEB Advanced Analytics Cloud Solution breaks new ground in SJun 24, 2016Other filingsASX
Medibios first commercial pilot study a successMay 30, 2016Other filingsASX
Appendix 4C - quarterly & activities reportMay 1, 2016Quarterly reportASX
Medibio Acquires Key IPApr 19, 2016Acquisition or disposalASX
Successful Pre-Submission Meeting with the US FDAMar 31, 2016Other filingsASX
Medibio appoints US based CRO for its validation trialsMar 30, 2016Other filingsASX
4 leading US Institutions provide Medibio 10,000 data setsMar 11, 2016Other filingsASX
Swinburne Software Labs trial success with Apple Watch & FITMar 8, 2016Other filingsASX
Partnership to evaluate wearable applications for Mental HeaFeb 11, 2016Other filingsASX
MEB signs MOU with $100 billion NYSE listed medical companyFeb 10, 2016Other filingsASX
BPO: BioProspect and Solagran agreement to commercialiseFeb 25, 2010Other filingsASX

Open Filings

Cap table

Built by 6ix from TrivarX Limited’s releases

Common shares
1,153,693,464
Fully diluted
1,153,693,464

Fully diluted

LineShares
Common shares1,153,693,464

Share count over time

CountShares
Nov 22, 20261,153,693,464

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Chris NtoumenopoulosNon-executive Director · Since at least Nov 12, 2026
Danielle MeyrickChief Executive Officer · Since at least Nov 11, 2026
David TrimboliNon-executive Chairman · Since at least Nov 12, 2026
Kai SunChief Operating Officer · Since at least Nov 11, 2026
Tony KeatingExecutive Director · Since at least Nov 12, 2026

Open People

Log in to ask 6ix AI your own questions about TrivarX Limited.